Literature DB >> 9169736

Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.

Z Kossaczka1, S Bystricky, D A Bryla, J Shiloach, J B Robbins, S C Szu.   

Abstract

The Vi capsular polysaccharide of Salmonella typhi, a licensed vaccine for typhoid fever in individuals > or = 5 years old, induces low and short-lived antibodies in children, and reinjection does not elicit booster responses at any age. Its immunogenicity was improved by binding Vi to proteins by using N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) as a linker. Similar findings were observed with the structurally related, di-O-acetyl derivative of pectin [poly-alpha(1-->4)-D-GalpA] designated OAcP. Protein conjugates of Vi and OAcP were synthesized by carbodiimide-mediated synthesis with adipic acid dihydrazide (ADH) as the linker. Hydrazide groups were introduced into proteins (bovine serum albumin or recombinant Pseudomonas aeruginosa exoprotein A) by treatment with ADH and 1-ethyl-3(3-dimethylaminopropyl carbodiimide (EDC). The resultant adipic acid hydrazide derivatives (AH-proteins), containing 2.3 to 3.4% AH, had antigenic and physicochemical properties similar to those of the native proteins. The AH-proteins were bound to Vi and OAcP by treatment with EDC. The immunogenicity of Vi or OAcP, alone or as protein conjugates, was evaluated in young outbred mice and guinea pigs by subcutaneous injection of 2.5 and 5.0 microg, respectively, of polysaccharide, and antibodies were measured by enzyme-linked immunosorbent assay. All conjugates were significantly more immunogenic than Vi or OAcP alone and induced booster responses with 5- to 25-fold increases of antibodies. Vi conjugates were significantly more immunogenic than their OAcP analogs. A carboxymethyl derivative of yeast beta-glucan enhanced the anti-Vi response elicited by an OAcP conjugate but had no effect on the immunogenicity of Vi or of OAcP alone. Vi and OAcP conjugates synthesized by this scheme will be evaluated clinically.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169736      PMCID: PMC175288          DOI: 10.1128/iai.65.6.2088-2093.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Studies on Vi antigen. VII. Characteristics of the immune response in the mouse.

Authors:  M LANDY
Journal:  Am J Hyg       Date:  1957-01

2.  Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.

Authors:  K P Klugman; I T Gilbertson; H J Koornhof; J B Robbins; R Schneerson; D Schulz; M Cadoz; J Armand
Journal:  Lancet       Date:  1987-11-21       Impact factor: 79.321

3.  Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys.

Authors:  C C Peeters; D Evenberg; P Hoogerhout; H Käyhty; L Saarinen; C A van Boeckel; G A van der Marel; J H van Boom; J T Poolman
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

4.  A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice.

Authors:  C C Peeters; A M Tenbergen-Meekes; D E Evenberg; J T Poolman; B J Zegers; G T Rijkers
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

5.  Relation between structure and immunologic properties of the Vi capsular polysaccharide.

Authors:  S C Szu; X R Li; A L Stone; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

6.  Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines.

Authors:  W A Keitel; N L Bond; J M Zahradnik; T A Cramton; J B Robbins
Journal:  Vaccine       Date:  1994       Impact factor: 3.641

7.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

8.  Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.

Authors:  C Chu; R Schneerson; J B Robbins; S C Rastogi
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.

Authors:  P Anderson; M E Pichichero; R A Insel
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

10.  Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.

Authors:  S C Szu; S Bystricky; M Hinojosa-Ahumada; W Egan; J B Robbins
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.609

View more
  18 in total

1.  Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.

Authors:  Shousun C Szu; Kimi F-Y Lin; Steven Hunt; Chiayung Chu; Nguyen Duc Thinh
Journal:  Vaccine       Date:  2014-03-21       Impact factor: 3.641

2.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

3.  Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.

Authors:  Z Kossaczka; S C Szu
Journal:  Glycoconj J       Date:  2000-06       Impact factor: 2.916

4.  Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.

Authors:  Margret Y Richter; Havard Jakobsen; Jean-François Haeuw; Ultan F Power; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.

Authors:  Vu Dinh Thiem; Feng-Ying C Lin; Do Gia Canh; Nguyen Hong Son; Dang Duc Anh; Nguyen Duc Mao; Chiayung Chu; Steven W Hunt; John B Robbins; Rachel Schneerson; Shousun C Szu
Journal:  Clin Vaccine Immunol       Date:  2011-03-16

6.  Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.

Authors:  So Jung An; Puthupparampil V Scaria; Beth Chen; Emma Barnafo; Olga Muratova; Charles Anderson; Lynn Lambert; Myung Hwa Chae; Jae Seung Yang; Patrick E Duffy
Journal:  Vaccine       Date:  2018-04-20       Impact factor: 3.641

7.  Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

Authors:  F Micoli; S Rondini; I Pisoni; D Proietti; F Berti; P Costantino; R Rappuoli; S Szu; A Saul; L B Martin
Journal:  Vaccine       Date:  2010-11-27       Impact factor: 3.641

8.  Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines.

Authors:  Erman Tritama; Catur Riani; Indra Rudiansyah; Arip Hidayat; Siti Azizah Kharisnaeni; Debbie Sofie Retnoningrum
Journal:  Hum Vaccin Immunother       Date:  2018-02-21       Impact factor: 3.452

9.  Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Authors:  Margret Y Richter; Håvard Jakobsen; Alda Birgisdottir; Jean-François Haeuw; Ultan F Power; Giuseppe Del Giudice; Antonella Bartoloni; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph™) in Children.

Authors:  Balaji Chinnasami; Kanimozhi Sadasivam; Aravindhan Vivekanandhan; Prema Arunachalam; Sekar Pasupathy
Journal:  J Clin Diagn Res       Date:  2015-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.